Peptide YY (PYY): The Satiety Hormone Explained

Key Takeaways

• What it is: A 36-amino acid peptide hormone produced by intestinal L-cells; its biologically active circulating form is PYY3-36, generated by DPP-IV cleavage of the N-terminal dipeptide.
• Primary function: Postprandial satiety signaling — PYY3-36 binds Y2 receptors in the hypothalamic arcuate nucleus, inhibiting NPY neurons and reducing appetite after meals.
• Co-secretion: PYY is co-secreted with GLP-1 from the same intestinal L-cells; the two hormones act additively on appetite suppression and are both elevated after bariatric surgery.
• Clinical relevance: PYY levels are elevated after bariatric surgery and are studied as a therapeutic target for obesity; dietary protein and fiber consumption raise PYY release.
• Therapeutic development: As of April 2026, no PYY analog holds FDA approval; PYY3-36 combined with GLP-1 receptor agonists is an active research direction for obesity combination therapy.

What Peptide YY Is

Peptide YY (PYY), also called peptide tyrosine-tyrosine, is a 36-amino acid gut hormone first isolated from porcine intestinal tissue. It is produced and secreted by L-cells in the distal small intestine and colon after food is consumed. Its primary role is satiety signaling: PYY acts as a physiological brake on food intake, rising after a meal and declining as the stomach empties over the following hours. Vincent and le Roux, writing in the Journal of Clinical Pathology in 2008, described PYY as a 36-amino acid gut hormone with therapeutic potential for obesity, providing the foundational clinical characterization. Stanley, Wynne, and Bloom, writing in the American Journal of Physiology: Gastrointestinal and Liver Physiology in 2004, reviewed PYY among L-cell-derived peptides involved in satiety, positioning it within the larger gut peptide hormone family that includes GLP-1, GLP-2, oxyntomodulin, and cholecystokinin.

Because PYY is co-secreted with GLP-1 from the same intestinal L-cells, understanding its biology is directly relevant to anyone exploring the gut-hormone mechanisms that underlie weight management. The GLP-1 receptor agonist drug class — including semaglutide and the dual GIP/GLP-1 receptor agonist tirzepatide — mimics one component of the postprandial gut hormone response; PYY represents a parallel and additive component that the body releases simultaneously from the same cells.

Discovery and history

PYY was first isolated by Tatemoto and Mutt in 1980 from porcine intestine during a systematic search for new gut peptides using an amide-content assay, as reported in their landmark Nature paper on isolation of two novel candidate hormones. The name reflects the molecule's structure: both the N-terminal and C-terminal residues are tyrosine (single-letter code Y), and the hormone belongs to the PP-fold (pancreatic polypeptide fold) structural family that also includes neuropeptide Y and pancreatic polypeptide. Early characterization established PYY's colonic distribution and postprandial release pattern. The discovery that PYY was elevated in patients with extreme short gut syndrome — with massively elevated circulating PYY and profound anorexia — suggested a pathological correlation between PYY and appetite suppression before mechanistic studies confirmed the relationship. The clinical significance of PYY's satiety function became clear in the early 2000s with landmark human infusion studies.

How PYY Suppresses Appetite

PYY's appetite-suppressive mechanism involves peripheral release, central receptor activation, and integration with energy balance circuits in the hypothalamus and brainstem. The pathway from L-cell secretion to reduced food intake involves multiple steps, each of which has been characterized in rodent models and human studies.

From L-cell to circulation: the two PYY forms

PYY is synthesized in intestinal L-cells as the full-length 36-amino-acid peptide (PYY1-36). After secretion, circulating DPP-IV rapidly cleaves the N-terminal tyrosine-proline dipeptide to generate PYY3-36, which becomes the predominant circulating form in the postprandial state. This cleavage is biologically meaningful, not merely a degradation step. Ballantyne, writing in Obesity Surgery in 2006, reviewed the two PYY forms and their different receptor preferences: PYY1-36 binds all Y receptor subtypes (Y1, Y2, Y4, Y5) with broadly similar affinity, while PYY3-36 shows preferential selectivity for the Y2 receptor subtype. The Y2 receptor is the anorexigenic receptor in the hypothalamic arcuate nucleus; the Y1 and Y5 receptors, by contrast, mediate orexigenic (appetite-stimulating) effects when activated by neuropeptide Y. DPP-IV cleavage therefore shifts PYY from a pan-Y-receptor ligand to a relatively selective Y2 agonist — a conversion that converts a broadly acting peptide into a targeted satiety signal.

The practical consequence: the same DPP-IV enzyme that inactivates GLP-1 activates PYY by cleaving its N-terminus into the receptor-selective form. DPP-IV inhibitor drugs, while preserving GLP-1, do not preserve PYY3-36 — they would actually reduce its formation.

Y2 receptor activation in the hypothalamic arcuate nucleus

The primary site of PYY3-36 action in the brain is the arcuate nucleus of the hypothalamus, a key node in the body's energy balance circuit. Arcuate neurons expressing neuropeptide Y (NPY) and Agouti-related protein (AgRP) are primary orexigenic drivers — when activated, they stimulate food intake. These neurons express Y2 receptors on their presynaptic terminals. When PYY3-36 binds Y2 receptors, it inhibits NPY/AgRP neuron activity, reducing orexigenic drive and shifting the hypothalamic balance toward satiety. Lafferty, Flatt, and Irwin, writing in Peptides in 2018, reviewed PYY3-36 acting through hypothalamic Y2 receptors and its therapeutic potential for obesity and type 2 diabetes. Liu, Ren, Zhang, and Ma, writing in Frontiers in Endocrinology in 2026, confirmed PYY3-36's Y2-mediated hypothalamic mechanism and additionally identified associations with improved insulin resistance, suggesting metabolic effects that extend beyond appetite control.

Beyond the arcuate nucleus, PYY may also act through the vagus nerve (which projects between the gut and brainstem) and directly on brainstem circuits. Romijn and colleagues, writing in Current Opinion in Clinical Nutrition and Metabolic Care in 2008, reviewed PYY's role in the gut-brain axis for satiety, and Valassi, Scacchi, and Cavagnini, writing in Nutrition, Metabolism and Cardiovascular Diseases in 2008, reviewed central and peripheral appetite regulation including PYY satiety pathways. Chaudhri, Field, and Bloom, in International Journal of Obesity in 2008, reviewed gut peptide hormones including PYY as physiological appetite regulators.

The ileal brake: a broader role in gastrointestinal motility

In addition to central appetite suppression, PYY contributes to the "ileal brake" — a physiological mechanism by which nutrients in the distal small intestine slow gastric emptying, reduce gastric acid secretion, and inhibit intestinal motility to allow more time for nutrient absorption. This peripheral effect is separate from and complementary to PYY's central hypothalamic action. Slowing gastric emptying after a high-fat or high-calorie meal reduces the rate of nutrient delivery to the small intestine, helping to prevent excessive postprandial glucose excursions and allowing more time for absorptive processes. The ileal brake mechanism is one of the proposed reasons fat-rich meals have been reported to produce a more sustained satiety signal than isocaloric carbohydrate-rich meals in controlled feeding studies, although Wilbrink and colleagues' 2021 review in Nutrients found the intestinal brake effect is not macronutrient-specific at equicaloric amounts — a qualification worth noting.

PYY and GLP-1: A Co-Secreted Satiety Pair

PYY and GLP-1 are the two primary satiety hormones released by intestinal L-cells after eating. Both are released in proportion to the caloric content and macronutrient composition of the meal; both rise within 15-30 minutes of food ingestion; both signal to the hypothalamus and brainstem to reduce appetite. Their functional relationship goes beyond co-location.

• PYY3-36:
  • Key structural feature: 34-amino-acid peptide (after DPP-IV cleavage of PYY1-36) with C-terminal amidation; hairpin PP-fold structure.
  • Primary mechanism: Y2 receptor agonism in the hypothalamic arcuate nucleus; inhibition of NPY/AgRP neurons; reduction of food intake.
  • Where the research stands: Batterham and colleagues' 2003 NEJM human infusion study demonstrated approximately 30% caloric intake reduction; elevated after bariatric surgery; combination with GLP-1 agonists is an active therapeutic direction.
• GLP-1:
  • Key structural feature: 30-amino-acid incretin hormone co-released from L-cells; structurally unrelated to PYY but co-secreted in parallel.
  • Primary mechanism: GLP-1 receptor (GLP-1R) agonism on pancreatic beta cells (insulin secretion), hypothalamus and brainstem (satiety), and vagal afferents; additive to PYY3-36 on appetite suppression.
  • Where the research stands: GLP-1 is the endogenous template for the most clinically successful peptide drug class of the 2020s; Andersen and colleagues' 2018 Nature Reviews Endocrinology review is the authoritative reference.
• Co-secretion and additive effects:
  • Key finding: Neary and colleagues, in Endocrinology in 2005, showed PYY3-36 and GLP-1 act additively to suppress food intake, with the combination reducing caloric intake significantly more than either hormone alone.
  • Bariatric relevance: Svane and colleagues demonstrated in 2016 that both PYY and GLP-1 rise substantially after RYGB surgery, and both contribute to the post-surgical reduction in food intake. Papamargaritis and le Roux, writing in Nutrients in 2021, reviewed evidence for gut hormones including PYY driving bariatric outcomes.
  • Drug development implication: The additive interaction between PYY and GLP-1 has motivated investigation of dual PYY-GLP-1 combination therapies, recognizing that a drug that mimics only one arm of the L-cell secretion profile may achieve less satiety than one that activates both pathways.

What the Evidence Shows

The human evidence for PYY's role in appetite regulation is more robust than for most gut peptide hormones, anchored by a widely cited intravenous infusion trial that directly tested PYY's effect on caloric intake in both lean and obese participants.

NEJM infusion study: PYY3-36 reduces caloric intake in lean and obese participants

Batterham, Cohen, Ellis, le Roux, Withers, Frost, Ghatei, and Bloom, publishing in the New England Journal of Medicine in 2003, administered PYY3-36 intravenously to lean and obese volunteers in a placebo-controlled crossover design and measured ad libitum food intake at a buffet. The study reported approximately 30% reduction in caloric intake at a single ad libitum test meal following PYY3-36 infusion compared to placebo — a finding that distinguished PYY's satiety mechanism from leptin resistance, which characterizes obesity. The result was significant for two reasons: it demonstrated that PYY3-36 reduces food intake in humans at physiological concentrations, and it showed that obesity does not blunt this response in the way it blunts leptin signaling. Hanusch-Enserer and Roden, writing in the European Journal of Clinical Investigation in 2005, reviewed PYY's role in counteracting ghrelin and reducing caloric intake, including the post-bariatric context.

Dietary and circadian factors affecting PYY

Gumus Balikcioglu and colleagues, in a clinical study published in the Journal of Clinical Endocrinology and Metabolism in 2015, examined how macronutrients affect PYY release, documenting differences in PYY response between protein, fat, and carbohydrate meals. Chambers and colleagues' 2015 Gut study showed colonic propionate delivery raises PYY, providing a direct mechanistic link between dietary fiber fermentation, short-chain fatty acid production, and the satiety hormone response. Ribeiro and colleagues, writing in Peptides in 2025, reviewed PYY and other peptides in circadian regulation of energy homeostasis, suggesting that PYY levels fluctuate with circadian patterns independent of meal timing.

Evidence gaps and limitations

Despite the Batterham NEJM finding, translating PYY3-36 into a clinical therapeutic has been difficult. Early attempts at intranasal PYY delivery failed to show consistent efficacy. Injectable PYY3-36 at doses required for efficacy produced nausea in some studies. Steinert and colleagues, writing in the American Journal of Clinical Nutrition in 2010, examined PYY3-36's effects on food intake in humans in the context of dose and delivery optimization. The field has moved toward longer-acting analogs and combination approaches. Macanhã Scremin and colleagues' 2026 study showing that PYY alone does not explain variable RYGB outcomes is a useful reminder that PYY is one component of a complex hormonal milieu, not a single-factor explanation for bariatric surgery's weight loss efficacy. Khan and colleagues, writing in Molecular and Cellular Endocrinology in 2025, reviewed PYY among gut hormones modulating appetite via the gut-brain axis, providing current context for where PYY sits within the broader hormonal appetite regulation landscape.

How PYY Connects to Measurable Biomarkers

PYY itself is not measured in standard clinical practice — no routine clinical blood test reports PYY. Its activity is inferred from the downstream measures of appetite regulation, metabolic function, and gut hormone system activity. For anyone interested in the biology underlying weight regulation, the most relevant measurable biomarkers are those that reflect the systems PYY acts within.

• Fasting insulin: Reflects the basal insulin-glucagon balance and insulin sensitivity — the same metabolic context in which PYY operates. Liu and colleagues' 2026 review found PYY3-36 associations with improved insulin resistance, suggesting PYY's effects extend into the same metabolic territory tracked by fasting insulin. Elevated fasting insulin often indicates metabolic conditions in which gut hormone satiety signaling is relevant.
• Fasting glucose: A primary metabolic marker in obesity and type 2 diabetes contexts where PYY signaling is relevant. Lafferty and colleagues' review of PYY's therapeutic potential for obesity and diabetes establishes its relevance to the glycemic system tracked by fasting glucose.
• HbA1c: Reflects 90-day average glycemic exposure. In the clinical context of obesity and insulin resistance where PYY research is most active, HbA1c provides the integrated metabolic picture that complements fasting glucose. Tan and colleagues' PYY analog trial used HbA1c as one outcome measure.
• Triglycerides: A systemic marker of fat metabolism and insulin sensitivity. In the context of bariatric surgery, where PYY rises dramatically, triglycerides typically fall substantially — a downstream reflection of the improved insulin-glucagon balance and reduced caloric intake that elevated PYY partially mediates.

For anyone exploring the biology of gut hormones and weight regulation, establishing metabolic baselines through fasting insulin, glucose, HbA1c, and a lipid panel provides the objective context for understanding where the PYY-GLP-1 signaling system is functioning optimally or is under strain. The biomarkers relevant to metabolic health and weight loss collectively reflect the systems that PYY-mediated satiety signaling influences.

When to Take This Seriously

Persistent difficulty with hunger control, satiety that resolves too quickly after meals, or patterns of eating that feel biologically driven rather than purely behavioral — these are common experiences that often have a hormonal substrate. The gut-brain axis hormones (GLP-1, PYY, ghrelin, cholecystokinin) are not peripheral players in this biology; they are the primary mediators of meal-to-meal appetite regulation, and their signaling patterns differ across individuals.

The clinical assessment of appetite dysregulation starts with the metabolic context: fasting insulin, glucose, HbA1c, and a lipid panel characterize the metabolic conditions in which gut hormone signaling operates. Identifying where those markers stand provides one objective reference point for evaluating whether the underlying biology is within expected ranges. That principle — understanding your biology before acting on it — is central to Superpower's approach to preventive health: objective biomarker data provides an evidence base for clinical conversations about complex biological systems like the gut-brain satiety axis.